hOMSC300 / Cytora - LARVOL DELTA

Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA) (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: Cytora Ltd. | Recruiting ➔ Active, not recruiting | Phase classification: P1/2 ➔ P1 | N=18 ➔ 10

Enrollment change • Enrollment closed • Phase classification • CNS Disorders • Movement Disorders • Multiple System Atrophy

Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early- to Moderate Stage MSA (clinicaltrials.gov) - P1/2 | N=18 | Recruiting | Sponsor: Cytora Ltd.

New P1/2 trial • CNS Disorders • Movement Disorders • Multiple System Atrophy